Loading...
Loading...
Valeant Pharmaceuticals International
VRX posted a loss in the third quarter.
Valeant cut its full-year revenue forecast to a range of $5.7 billion to $5.9 billion, versus its earlier outlook of $5.8 billion to $6.2 billion.
Valeant posted a quarterly loss of $973.2 million, or $2.92 per share, versus a year-ago profit of $7.6 million, or $0.02 per share. Excluding special items, its cash earnings climbed to $1.43 per share from $1.15 per share.
Its revenue surged 74% to $1.54 billion. However, analysts were expecting earnings of $1.42 per share on revenue of $1.67 billion.
Valeant shares fell 3.62% to $105.11 in pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in